Noonan syndrome is a common autosomal dominant disorder characterized by short stature, congenital heart disease and facial dysmorphia with an incidence of 1/1000 to 2500 live births. Up to now, several genes have been proven to be involved in the disturbance of the transduction signal through the RAS-MAP Kinase pathway and the manifestation of Noonan syndrome. The first gene described was PTPN11, followed by SOS1, RAF1, KRAS, BRAF, NRAS, MAP2K1, and RIT1, and recently SOS2, LZTR1, and A2ML1, among others. Progressively, the physiopathology and molecular etiology of most signs of Noonan syndrome have been demonstrated, and inheritance patterns as well as genetic counseling have been established. In this review, we summarize the data concerning clinical features frequently observed in Noonan syndrome, and then, we describe the molecular etiology as well as the physiopathology of most Noonan syndrome-causing genes. In the second part of this review, we assess the mutational rate of Noonan syndrome-causing genes reported up to now in most screening studies. This review should give clinicians as well as geneticists a full view of the molecular aspects of Noonan syndrome and the authentic prevalence of the mutational events of its causing-genes. It will also facilitate laying the groundwork for future molecular diagnosis research, and the development of novel treatment strategies.
Keywords: CDC25, cell division cycle 25; CHD, congenital heart defects; CR, conserved region; CRD, cysteine-rich domain; GAP, GTPase activating protein; GDP, guanosine-DiPhosphate; GEF, guanine exchange factor; GH, growth hormone; GTP, guanosine-TriPhosphate; HCM, hypertrophic cardiomyopathy; IGF-1, insulin-like growth factor I; MAP kinase signaling pathways; Molecular etiology; Mutation rate; Noonan syndrome; PTPN11; RAS family; RBD, RAS binding domain; REM, RAS exchange motif.